Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone + aripiprazole is a combination therapy being investigated primarily for alcohol dependence treatment. Naltrexone is an opioid antagonist that blocks opioid receptors, reducing alcohol cravings and rewarding effects of alcohol. It's available as oral tablets and monthly injections (Vivitrol). Aripiprazole is an atypical antipsychotic that functions as a dopamine/serotonin system stabilizer, acting as a partial dopamine agonist that blocks dopamine at higher concentrations and augments it at lower concentrations. This combination targets multiple neurotransmitter systems involved in addiction, potentially enhancing efficacy compared to either medication alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naltrexone + aripiprazole.